BCRX · XBRL financial data

Biocryst Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of goods and services sold	1	2*	1	2	3	6*	5	3	2	10*	5	4
Research and development	47	70*	46	38	41	49*	37	43	45	41*	60	52
Selling, general and administrative	51	64*	59	61	65	80*	82	87	83	96*	95	64
Operating income (loss)	(12)	(43)*	(14)	9	8	(5)*	21	30	30	260*	(702)	98
Interest expense	27	25*	25	25	25	24*	23	22	20	14*	20	22
Other income (expense)	—	—	—	—	—	—	0	0	—	—	(1)	0
Income tax expense (benefit)	0	(1)*	0	0	1	1*	1	1	(1)	2*	1	1
Net income (loss)	(36)	(62)*	(35)	(13)	(14)	(27)*	0	5	13	246*	(722)	78
Earnings per share, basic USD per share	(0.19)	(0.31)*	(0.17)	(0.06)	(0.07)	(0.13)*	0.00	0.02	0.06	1.17*	(2.98)	0.31
Earnings per share, diluted USD per share	(0.19)	(0.31)*	(0.17)	(0.06)	(0.07)	(0.13)*	0.00	0.02	0.06	1.12*	(2.98)	0.30
Weighted average shares, basic millions of shares	190	201*	206	206	207	207*	209	210	210	211*	242	254
Weighted average shares, diluted millions of shares	190	201*	206	206	207	207*	215	220	220	219*	242	265

Fiscal quarters (BCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	151	111	84	78	97	105	105	88	84	90	172	155
Short-term investments	—	—	—	—	—	216	190	172	129	185	67	198
Marketable securities	247	278	252	194	233	216	—	—	—	—	—	—
Accounts receivable	54	57	61	69	72	79	93	91	91	107	109	111
Inventory	30	29	30	4	8	31	7	5	5	5	6	6
Prepaid and other current assets	20	20	18	16	16	14	14	13	17	17	19	15
Total current assets	502	496	447	363	427	422	410	398	356	404	374	485
Property and equipment, net	9	8	8	8	7	8	8	8	8	9	9	9
Right-of-use asset	11	9	9	9	8	8	8	8	8	8	—	—
Total assets	523	517	468	472	491	490	480	457	446	514	465	558
Accounts payable	11	21	12	8	13	12	10	9	6	16	11	11
Accrued liabilities	77	103	79	90	104	113	93	107	119	126	119	122
Total current liabilities	91	150	120	129	154	160	140	177	190	196	195	209
Long-term debt	298	303	308	314	314	315	315	243	194	0	395	395
Lease liability, non-current	10	8	9	8	8	8	8	8	8	9	11	11
Total liabilities	—	972	—	—	960	966	932	879	834	633	1,019	1,012
Accumulated deficit	(1,619)	(1,681)	(1,717)	(1,729)	(1,743)	(1,770)	(1,770)	(1,765)	(1,752)	(1,506)	(2,228)	(2,150)
Total stockholders' equity	(411)	(456)	(476)	(476)	(469)	(476)	(452)	(422)	(388)	(119)	(554)	(454)
Total liabilities and equity	523	517	468	472	491	490	480	457	446	514	465	558
Common shares outstanding (cover page) millions of shares	205	206	206	207	207	209	209	210	211	251	254	256

Fiscal quarters (BCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(36)	(62)*	(35)	(13)	(14)	(27)*	0	5	13	246*	(722)	78
Stock-based compensation	12*	16*	14	13*	17*	21*	21	21*	19*	24*	16	15*
Depreciation and amortization	0*	0*	0	0*	0*	0*	0	0*	0*	0*	—	—
Net cash from operating activities	(20)*	(9)*	(54)	(1)*	8*	(5)*	(28)	41*	42*	year only	(62)	104*
Net cash from investing activities	23*	(28)*	29	(2)*	8*	18*	27	29*	14*	(83)*	(269)	(110)*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	—	—	—	—
Proceeds from long-term debt	0*	0*	—	—	0*	0*	0	0*	—	year only	400	0*
Repayments of long-term debt	—	year only	—	—	0*	0*	—	—	46*	184*	—	—
Net cash from financing activities	1*	(3)*	(1)	(2)*	1*	(4)*	1	(74)*	(59)*	(218)*	413	(11)*
Net change in cash	5*	(40)*	(26)	(6)*	19*	7*	1	(17)*	—	year only	82	(17)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.